WO1998025634A1 - Serum-derived factor inducing cell differentiation and medical uses thereof - Google Patents
Serum-derived factor inducing cell differentiation and medical uses thereof Download PDFInfo
- Publication number
- WO1998025634A1 WO1998025634A1 PCT/IL1997/000395 IL9700395W WO9825634A1 WO 1998025634 A1 WO1998025634 A1 WO 1998025634A1 IL 9700395 W IL9700395 W IL 9700395W WO 9825634 A1 WO9825634 A1 WO 9825634A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sdf
- cells
- complex
- fraction
- acetonitrile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm, to methods for the isolation thereof and to pharmaceutical compositions comprising the same.
- SDF serum-derived composition of matter
- BACKGROUND OF THE INVENTION Normal hemopoiesis is coordinated by a variety of regulators which include glycoprotein growth factors (cytokines), such as the colony stimulating factors, as well as non-protein small molecules such as the retinoids. They regulate the survival (apoptosis), proliferation and differentiation of progenitor and precursor cells and the activation state of mature cells. Both proliferation and differentiation processes are regulated by positive and negative stimuli. In acute leukemia, a block in the cell differentiation leads to a massive accumulation of proliferative, undifferentiated non-functional cells. Recently, these regulators have been used in a wide array of clinical and laboratory applications.
- cytokines are used for treatment of patients with aplastic states such as post bone marrow (BM) transplantation, radio-chemotherapy etc., as well as for ex vivo expansion of specific subsets of cells valuable in cell therapy (transplantation, immuno- or gene-therapy).
- aplastic states such as post bone marrow (BM) transplantation, radio-chemotherapy etc.
- radio-chemotherapy etc.
- ex vivo expansion of specific subsets of cells valuable in cell therapy transplantation, immuno- or gene-therapy.
- Low molecular weight compounds such as retinoids, have been used for induction of differentiation in leukemic cells as a therapeutic modality.
- the current approach to treatment of leukemia is based on killing the malignant cells by chemo- or radiotherapy. Such treatment is not specific to the malignant cells and damages also dividing normal cells. Therefore, an alternative approach is being developed, based on inducing, the undifferentiated leukemic cells to undergo differentiation. Evidently, terminal differentiation of hemopoietic cells is associated with loss of leukemogenicity.
- cytokines e.g. IL-6
- IL-6 cytokines
- Shabo Y., et al, Blood 78:2070 (1988); Fibach, E., et al, Proc. Natl. Acad. Sci. USA 70:343-346 (1973); Inbar, M., et al, Proc. Natl. Acad. Sci. USA 70:2577-2581 (1973); Fibach, E. & Sachs, L.
- differentiation inducers include dimethylsulfoxide, hexamethylene bis- acetamide, butyric acid [Collins, S.J., et al, Proc. Natl. Acad. Sci. USA 75:2458 (1978)], derivatives of vitamins A and D3 [Breitman, T.T., et al, Proc. Natl. Acad. Sci. USA 77:2936 (1980)] and low doses of cytotoxic drugs such as actinomycin D and cytosine arabinoside [Breitman, T.T., et al, ibid.].
- Retinoic acid has been used in the treatment of acute promyelocytic leukemia [Chomienne, C, FASEB 10: 1025 (1996)].
- JP 56120622 and JP 56090015 CP is described as the active ingredient in an antitumor preparation against leukemia.
- JP 56120622 describes the
- CP as having a therapeutic activity against several mammalian tumors due to its inhibitory effect on aggravation of cancer.
- CP is described as being capable of inactivating the strong oxidative super-oxide anion radicals by converting them into oxygen molecules. It is also mentioned that CP has an effect on the promotion of liver catalase biosynthesis.
- JP56090015 describes a preventative and remedial drug for side reactions of anti- malignant tumor agents, which contains human CP as the main ingredient.
- JP 56002916 also describes CP as an anti-tumor agent.
- This publication is concerned with compositions for the prevention and treatment of radiation damages which contain CP as the active ingredient. Animals irradiated with ⁇ -rays, after pre- incubation with a composition comprising CP, showed a high survival rate. The preventive activity described in this publication was specifically attributed to CP.
- JP 60149529 relates to the production of differentiation-inducing factors, as a result of administration of CP to mammals.
- medicines for leukemia in which the active ingredients are the differentiation-inducing factors produced after treating mammals with CP are described.
- the differentiation of leukemic cells obtained by the differentiation-inducing factors is induced via a CP stimulus.
- Serum obtained from rabbits which repeatedly received CP was capable of inducing differentiation of Ml cells into macrophages.
- CP by itself was incapable of inducing the differentiation. There is no indication as to the identity or nature of the substance obtained by CP stimulus, which causes the induction of differentiation.
- CP has been described also for the preparation of other pharmaceutical compositions.
- GB 1,304,697 describes pharmaceutical compositions comprising CP for use, in particular, against inflammation.
- CP may be helpful in therapy of aplastic anemia [Shimizu, M., Transfusion 19(6):742-8 (1979); Arimori, S., Jap. J. Clin. Exper. Med. 43: 1897 (1966)].
- SDF small molecular weight composition of matter
- SDF-CP complex a small molecular weight composition of matter
- CP derived from adult serum is a rich source of the factor.
- Other sources for SDF are urine and fetal serum. Due to its large molecular weight, intact CP cannot be present in the urine. Thus, it is assumed that the factor present in urine is not associated with the CP molecule, or at least not with the intact molecule.
- SDF as well as its complex with CP, which are the subject of the present invention, may have many therapeutical uses.
- the present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm.
- SDF serum-derived composition of matter
- the molecular weight of SDF, as determined by electron spray is 316.
- the invention in a second aspect, relates to a method for the isolation from plasma and purification of a low molecular weight composition of matter, comprising the steps of (a) transferring plasma through an affinity column to obtain an electrophoretically homogeneous fraction being the SDF-CP complex, which may be optionally concentrated by transferring through an anion exchange column; (b) isolating the SDF from the SDF-CP complex by either (i) transferring the fraction obtained in step (a) through RP-HPLC "Resource”TM column, elution buffer A consisting of 0.05-0.1% trifluoroacetic acid (TFA) in water (pH 2.5), elution buffer B consisting of acetonitrile, the fractions eluted at acetonitrile concentration of 0-2% and 13-17% being collected and combined, or (ii) extracting the fraction obtained in step (a) with an acidified solvent, wherein the active fraction is recovered from the organic phase; (c) purifying the fraction obtained in (b) by
- a biologically active complex comprising ceruloplasmin and said biologically active composition of matter (SDF).
- the invention in a second aspect, relates to pharmaceutical composition
- pharmaceutical composition comprising as active ingredient the SDF of the invention or its complex with CP, and optionally further comprising pharmaceutically acceptable additives.
- Such pharmaceutical compositions may be used for treatment of patients with aplastic marrow, for inducing or maintaining remission of tumors, for expanding hematopoietic normal stem and progenitor cells for bone marrow transplants or for inhibiting enhanced angiogenesis.
- Fig. 1 Affinity purification of the SDF-CP complex from plasma
- the fraction was separated from its complex and is depicted by the absorbance at 220 nm (A 22 o) as function of time (T(min.)).
- Buffer A 0.1% TFA in H2O (pH 2.5)
- buffer B 0.1% TFA in acetonitrile.
- the gradient is indicated as the acetonitrile percentage in the eluting buffer (ACN(%))
- SDF fraction is eluted in correlation with the void and after 5-6 min (a).
- PB cells Light density peripheral blood (PB) cells were cultured in liquid culture (phase I, as described in the Examples) supplemented with none (C, for control), 5637 CM (10% v/v, (CM)), SDF and SDF-CP complex (SDF- CP) at different dilutions. After 5 days the cells were harvested, washed and cloned in semi-solid medium supplemented with Epo. Colonies were scored on day 14 as illustrated in the figure by the number of erythroid colonies per plate (No. e.c/p).
- B Light density PB cells were cultured in liquid culture (phase I) supplemented with 5637 CM (10% v/v, (CM)) or SDF (1 :200, (SDF)).
- PB cells were cultured in liquid culture (phase I) supplemented with 5637 CM (10% v/v(CM)), stem cell factor (SCF) or SDF (SDF).
- CM stem cell factor
- SDF SDF
- PB cells Light density PB cells were cultured in liquid culture (phase I) supplemented with 5637 CM (10% v/v, (CM)), SDF or SDF + 5637 CM (SDF+CM). After 3-4 days, the cells were harvested, washed and cloned in semi-solid medium. Dendritic colonies (D.C %) were scored on day 14.
- Fig. 12 Effect of SDF on erythroid progenitors derived from pure red cell aplasia
- PB cells derived form a patient with pure red cell aplasia were cultured in liquid culture (phase I) supplemented with 5637 CM (10% v/v, (CM)) or SDF + 5637 CM (SDF+CM) with the different dilution of SDF indicated in the figure. After 4 days the cells were harvested, washed and cloned in semi-solid medium supplemented with
- Epo. Colonies were scored on day 14, and is depicted in the figure by the number of erythroid colonies per plate (No. e.c/p).
- Fig. 13 Effect of SDF on colony formation by leukemic and normal progenitors
- HL-60 cells Leukemic HL-60 cells (HL-60) and normal BM (NBM) progenitors were cloned in agarose cultures stimulated by GM-CSF (100 U/ml) and several dilutions of SDF (SDF(Dil.)). Colonies were scored on day 10. The results are illustrated as colony number as a function of the different SDF dilutions), for HL-60 cells, two sets of experiments (Exp. 1 and Exp. 2) were conducted.
- the present invention relates to a biologically active serum-derived composition of matter (SDF), having low molecular weight, being electrically charged at acidic pH, and having absorption at 280 nm.
- SDF serum-derived composition of matter
- the molecular weight of SDF being 316, as determined by electron spray mass spectrometry.
- SDF is comprised of an aromatic moiety, and carries a double charge, as indicated by the fragmentation thereof on electron spray mass spectrometry.
- the invention also relates to a method for the isolation and purification from plasma, of a low molecular weight composition of matter, comprising the steps of (a) transferring plasma through an affinity column to give an electrophoretically homogeneous fraction being the SDF-CP complex, which may optionally be concentrated by transferring through an anion exchange column and collecting the bound fraction, having an absorption at 280 nm; (b) isolating the SDF from its complex with the high MW CP protein by either (i) transferring the fraction obtained in step (a) through RP-HPLC "Resource”TM column, elution buffer A, consisting of 0.05-0.1% TFA in water (pH 2.5), and elution buffer B, consisting of acetonitrile, are employed, the active fractions eluted at acetonitrile concentration of 0-2% and 13-17% being collected and combined, said CP fraction being eluted at acetonitrile concentration of about 40% and being devoid of activity; or (ii) extract
- the affinity chromatography column employed in step (a) is preferably a tentacle-agarose gel, derived using a reaction of Sepharose CL-6B or Sepharose 4B with chloroethylamine [Calabrese, L., Biochem. Int. 16: 199-208 (1988)].
- the method of the invention thus further comprises (c) purifying the active fraction obtained in step (b) by RP-HPLC chromatography separation, using a C 18 column, wherein in a first optional separation step, elution buffer A, consisting of 0.1% TFA in water (pH 2.5), and elution buffer B, consisting of 0.1% TFA in acetonitrile, are employed, the fraction eluted at acetonitrile concentration of 0-2% being collected (void).
- This purification step at acidic pH (2.5) results in a partial disassociation of SDF from said impurities.
- the active fraction is eluted in correlation with the void volume, while most of the impurities are eluted with the gradient.
- the semi-purified SDF (in case the optional purification at acidic pH is employed) is then subjected to a subsequent separation step, by transferring the same through the same column, employing elution buffer A, consisting of 0.1% triethylamine in water, adjusted to pH 7.0, and elution buffer B, consisting of acetonitrile.
- elution buffer A consisting of 0.1% triethylamine in water, adjusted to pH 7.0
- elution buffer B consisting of acetonitrile.
- the fraction appearing as a single, symmetrical peak is eluted with acetonitrile concentration of 9-1 1% and collected.
- the fraction obtained from step (b) is directly separated on the second separation step of (c).
- a five-step purification procedure may be employed as an alternative to step (a).
- This five-step procedure comprises the steps of ammonium sulfate precipitation, anion exchange chromatography (DEAE), cation exchange chromatography (S- Sepharose), dye-ligand (Affigel blue) chromatography and hydrophobic chromatography (TSK-Phenil).
- the purified fraction may be further separated on an SDS-gel.
- the plasma from which SDF is obtained is human plasma.
- an active fraction is also present in non-human plasma, in human urine and in bovine fetal serum. Since the full CP protein is too large to be present in the urine, it is assumed that the active fraction present therein is the SDF itself or in association with part of the CP protein or with other small peptides.
- SDF may be isolated and purified from human or non-human adult or fetal serum or urine, by any suitable method.
- the invention also relates to a biologically active complex comprising CP and SDF.
- any biochemically pure SDF obtained by the method according to the invention are also within the scope of the present invention.
- the complex of SDF with CP can be obtained, for example, from step (v) of the five-step purification (Example IB) procedure or after the one step affinity purification procedure of the method of the invention.
- normal serum which sustains the growth and viability of cells in culture
- SDF serum-derived factor
- hemopoietic cells originally obtained from either autologous or allogeneic sources, has become the treatment of choice for a variety of inherited or malignant diseases. Recently, more defined populations, enriched for pluripotent hemopoietic stem cells (CD34 + cells) have been used in such treatments [Van Epps, D.E., et al, Blood Cells 20:411 (1994)]. In addition to bone marrow, stem cells could be derived from other sources, such as peripheral blood and neonatal umbilical cord blood [Emerson, S.G., Blood 87:3082 ( 1996)].
- transplantation with peripheral blood cells shortens the period of pancytopenia and reduces the risks of infection and bleeding [Brugger, W., et al, N. Engl. J. Med. 333:283 (1995); Williams, S.F., et al, Blood 87: 1687 (1996); Zimmerman, R.M., et al, J. Heamatotherapy 5:247 (1996)].
- An additional advantage of using peripheral blood for transplantation is its accessibility.
- the limiting factor in peripheral blood transplantation is the low number of circulating CD34+ cells.
- peripheral blood derived stem cells are "harvested" by repeated leukophoreses, following their mobilization from the marrow into the circulation after treatment with colony stimulating factors and chemotherapy [Brugger et al (1995), ibid.; Williams et al (1996) ibid.].
- the cultures may provide a significant depletion of T-lymphocytes, which may be useful in the allogeneic transplant setting for reducing graft-versus-host disease.
- Clinical studies have indicated that transplantation of ex vivo expanded cells derived from a small number of peripheral blood CD34+ cells can restore hemopoiesis in patients treated with high doses of chemotherapeutical agents. Nevertheless, the up to date results do not allow for firm conclusions about the long term in vivo hemopoietic capabilities of such cultured cells [Brugger et al. (1995) ibid.; Williams et al (1996) ibid.].
- ex vivo expanded cells will include, in addition to stem cells, more differentiated progenitors in order to optimize short-term recovery and long term restoration of hemopoiesis.
- expansion of intermediate and late progenitor cells especially those committed to the neutrophilic and megakaryocytic lineages, concomitant with expansion of stem cells, is required [Sandstrom, C.E., et al, Blood 6:958 (1995)].
- SDF myeloid leukemic cells
- SDF or its complex with CP is capable of stimulating proliferation of early, normal progenitor cells. Therefore SDF or its complex with CP may be used for ex vivo expansion of normal hematopoietic cells such as stem cells (CD34 + ) and myeloid and erythroid-committed progenitors as well as antigen-presenting dendritic cells, for BM transplantation treatment, or be utilized, for ex-vivo expansion of specific sub-populations that should be valuable in cell therapy (transplantation, and immuno- or gene therapy).
- SDF or its complex with CP can be applied in vivo, where they may support the recovery of the hemopoietic tissue in aplastic states such as in aplastic anemia or following radio/chemotherapy.
- Dendritic cells Ex vivo expansion of specific populations of subsets of lympho-hematopoietic cells with therapeutic potential such as the antigen presenting dendritic cells.
- Dendritic cells are "professional", immunostimulatory, antigen-presenting cells.
- dendritic cells in immunotherapy. This modality involves infusion of dendritic cells pulsed in vitro with tumor antigens as therapeutic vaccines, as well as using dendritic cells for priming tumor antigen specific T cells in vitro for use in adoptive T cell therapy [Bernhard, H., et al, Cancer Res. 55:1099 (1995); Protti, M.P., et al,
- SDF has a potent inhibitory activity on the proliferation of endothelial cells from bovine aorta.
- ex vivo expansion of hematopoietic stem cells using SDF or its complex with CP may be used in gene therapy.
- SDF or its complex with CP possess several therapeutical activities such as inducing differentiation and inhibiting proliferation of both human and murine established leukemic cell lines and of freshly explanted cells from acute and chronic human myeloid leukemias.
- SDF itself or its complex with CP are capable of inducing terminal cell differentiation of leukemic cells. Blast cells lose their leukemic phenotype and turn into functional, non-dividing macrophages.
- said leukemic cells in the presence of SDF or its complex with CP, lose their ability to proliferate and their ability for self cell renewal.
- SDF, or its complex with CP makes it potentially useful in the treatment of myeloid leukemias in three clinical settings: (a) for induction of remission, optionally, in combination with other hemopoietic factors or low-dose chemotherapy, using "differentiation- inducing therapy" as the main modality; (b) for maintenance of remission state of tumors and (c) in autologous transplantation, for either in vitro or in vivo purging of residual leukemic cells.
- SDF or its complex with CP may be utilized for regulating the proliferation and differentiation of hemopoietic cells, by modulating nuclear transcription factors.
- redox status could provide a general mechanism for post-translational control of transcription factors in an analogous fashion to phosphorylation [Xanthoudakis (1992) ibid.; Ammendola (1994) ibid.].
- redox regulation may be widespread because the DNA binding activities of several other transcription factors, including Myb, Rel, and NF-kB are sensitive to changes in their oxidation state in a similar manner.
- Recent disclosures suggest the contribution of small redox-potential molecules such as glutathion or large proteins such as thioredoxin [Walker, L.J., Mol. Cell. Biol. 13:5370 (1993)] to the regulation of DNA binding ability of several nuclear transcription factors like Sp- 1.
- small molecules with redox potential like pyrroloquinoline quinone (PQQ) stimulate proliferation [Naito, Y., Life Sciences 52: 1909 (1993)].
- PQQ pyrroloquinoline quinone
- the potency of PQQ was shown to be comparable to that of epidermal growth factor and is much higher than that of fibroblast growth factor or insulin growth factor.
- SDF was found to have a potent inhibitory activity on endothelial cell proliferation, and therefore it might be applicable for inhibiting angiogenesis
- angiogenesis is dramatically enhanced and is no longer self-limited.
- Pathological angiogenesis is seen during the development of many diseases, for example rheumatoid arthritis, psoriasis, retrolental fibroplasia, diabetic retinopathy and hemangiomas, during the rejection of organ transplants and most importantly in solid tumor malignancies.
- Well vascularized tumors expand both locally and by metastasis, while avascular tumors do not grow beyond a diameter of 1-2 mm. It has been suggested that this is the results of lack of balance between angiogeneic stimulators and inhibitors [Folkman,
- compositions comprising as active ingredient SDF or its complex with CP and optionally further comprising pharmaceutically acceptable additives are within the scope of the invention.
- Such pharmaceutical compositions may be used for inhibiting enhanced angiogenesis in diseases where uncontrolled angiogenesis is associated with the pathological manifestations.
- composition of the invention may be for inducing remission of tumors comprising as active ingredient the SDF of the invention, and optionally further comprising pharmaceutically acceptable additives.
- pharmaceutical composition of the invention can be used for maintaining tumor remission state comprising as active ingredient the SDF of the invention, and optionally further comprising pharmaceutically acceptable additives.
- compositions for expanding hematopoietic normal stem and progenitor bone marrow transplants comprising as active ingredient SDF, and optionally further comprising pharmaceutically acceptable additives are also with in the scope of the invention.
- the magnitude of therapeutic dose of the SDF on the invention will of course vary with the group of patients (age, sex etc.), the nature of the condition to be treated and with the route administration and will be determined by the attending physician.
- the pharmaceutical composition of the invention can be prepared in dosage units forms.
- the dosage forms may also include sustained release devices.
- the compositions may be prepared by any of the methods well-known in the art of pharmacy.
- compositions of the pharmaceutically acceptable additives may be any pharmaceutical acceptable carrier, excipient or stabilizer, and optionally other therapeutic constituents.
- the acceptable carriers, excipients or stabilizers are non-toxic to recipients at the dosages and concentrations employed.
- a human plasma was transferred through an affinity column.
- the affinity chromatography procedure is based in the tentacle-agarose gel procedure [Robert, V.S., Biochemistry International 27:281-289 (1992)], which preferentially binds the CP protein.
- the gel was derived by reacting Sepharose CL-6B or Sepharose 4B with chloroethylamine [Robert (1992) ibid.].
- the plasma may be precipitated by ammonium sulfate, at a cut-off of 30-60%. equilibrated in lOmM tris buffer pH 7.4, conductivity 5 ms and then separated on a tentacle-agarose gel as described above,. Elution was performed stepwise with: 0.1, 0.2, 0.3, 0.5, 1.0 M NaCl in tris buffer ( Figure 1).
- the fraction was transferred through an anion exchange column (DEAE, or QAE Sephadex columns).
- the column and the fraction were equilibrated with 300 mM NaCl in tris buffer.
- the bound fraction was eluted with 300 mM NaCl in tris buffer.
- step (ii) Anion exchange chromatography - The fraction obtained from step (i) was equilibrated with tris buffer 20 mM (pH 7.4), 120 mM NaCl (conductivity 120 mS), and pumped on a DEAE column (Pharmacia LKB Biotechnology AB, Uppsala Sweden, bed volume 1 liter (1 1.2dxl0h)), previously equilibrated with the same buffer at flow 2.5 L/hr. The column washed with the loading buffer until the effluent O.D. at 280 nm returned to the base-line.
- the elution buffer employed was a linear salt gradient from 120 mM NaCl to 500 mM NaCl in tris buffer. The activity was eluted with 300 mM NaCl.
- the DEAE-derived fractions were diluted v/v with tris buffer 25 mM (pH 7.4), 100 mM NaCl. n-Butanol was added dropwise while stirring until an upper butanol phase was obtained. After centrifugation the two phases (aqueous and butanolic) were collected separately. The butanolic phase was evaporated and redissolved in ethanol or in the tris buffer and assayed for activity. The aqueous phase was further separated on a DEAE column. The bound protein was step eluted with tris buffer (pH 7.4), lM NaCl. The activity was recovered from the bound fraction.
- Sepharose column (Pharmacia, 800 ml bed volume).
- Elution buffer A consisting of 20 mM acetate buffer (pH 5.0), 40 mM NaCl (conductivity 4 mS), elution buffer B consisting of 20 mM acetate buffer (pH 5.0), 0.6 mM NaCl.
- the column, equilibrated with buffer A was loaded with fraction, adjusted to the conditions of buffer A.
- Elution gradient employed was a linear salt gradient, starting from 100% buffer A, to 100% buffer B. The activity was eluted with
- Elution buffer A consisting of 50 mM tris buffer (pH 7.4), 24 mM KC1 and 2 mM ZnCl (conductivity 5.5 mS), elution buffer B consisting of 50 mM tris buffer (pH 7.4), 24 mM KC1 and buffer C consisting of 50 mM tris buffer (pH 7.4), 1 M KC1, were employed.
- the column previously equilibrated with buffer A was loaded with the active fraction which was adjusted to the conditions of buffer A and pumped at flow 3 ml/min.
- the protein was eluted with a step elution employing 100% buffer.
- the purified fraction may be separated on an SDS-gel: 70% of the activity was recovered from a protein band that correlates with MW of 97KD while 30% of the activity was recovered from a low MW fraction at the front of the gel.
- the 97KD band was sequenced and found to correspond to the copper binding protein- ceruloplasmin.
- the low MW fraction was also sequenced and analyzed by mass spectrum and found to contain several peptides of 1-2 KD MW.
- the complex was subjected to purification by steps (b) and (c) described above. SDF Isolation from its high MW complex with CP
- the SDF fraction can be isolated from the complex in two alternative procedures : A: RP-HPLC "Resource ' M chromatography - The active fraction was separated from 9 mg purified complex on a RP-HPLC column (3 ml, Pharmacia) comprised of polystyrene/divinyl benzene beads. (Fig. 2). Buffer A consisting of 0.1-0.05%) TFA in H2O, buffer B consisting of acetonitrile. flow 3 ml/min. absorption at A220- Two SDF peaks at 0-2% and 13-17% acetoniirile were detected and collected. B: solvent extraction - The active fraction was separated from its comp lex with CP by solvent extraction with an acidified solvent.
- a first purification step an elution buffer having a pH of 2.5 was employed, buffer A - 0.1 TFA in H2O, and buffer B - 0.1% TFA in acetonitrile.
- the SDF fraction was eluted with about 0-2% acetonitrile, after 5-6 min (Fig. 3), which correlated with the void volume.
- buffer A consisting of 1% triethylamine in water, adjusted to pH of 7.0 and buffer B consisting of acetonitrile were employed.
- SDF fraction was eluted with about 9-11% acetonitrile, after 11-12 min (Fig. 4).
- Mass spectroscopy (electron spray) analysis of the active fraction indicates the presence of a single compound with a molecular weight of 316 (317-1). Fragmentation of the molecule at cone voltage 30, 45 and 60 V is shown in Fig 8 (a- c). The 159 molecular mass fragment may represent half the mass of the compound. Such a half mass fragmentation is characteristic to a double charged molecule (M/2e). In addition, double charged ions are mostly found in spectra of highly unsaturated compounds (e.g. aromatics or N-containing aromatics).
- Cell lines included the human myelomonocytic cells HL-60, GM-CSF-dependent human myelomonocytic cells LK (established in the inventors' laboratory) and the murine monocytic cell line WEHI. Cell lines were maintained by sub-culturing every 3-4 days at 2.5xl0 5 cell/ml in either alpha minimal essential or RPMI-1640 media (GIBCO, Grand Island, NY) supplemented with 10-20% fetal calf serum (FCS) (Bio Labs Jerusalem. Israel). The cultures were incubated at 37°C, in a humidified atmosphere of 5% CO2 in air. The concentration of viable cells was determined by the trypan blue exclusion technique. Total cell count was performed using a Coulter counter.
- HL-60 or other cells were cultured at 1.3 x 10 5 /ml in 24-well dish and medium containing 0.5%) heat- inactivated FCS and various dilutions of the tested fractions.
- DNA synthesis was determined on day 4 by incorporation of 3 [H]-thymidine (lmci/150 ⁇ l) (5 mCi/mmol, ICN Radiochemicals, Irvine. CA) added 12 hrs before harvesting.
- 3 [H]-thymidine lmci/150 ⁇ l
- ICN Radiochemicals Irvine. CA
- One unit of SDF was defined as the amount per milliliter required for 50% decrease in 3 H-thymidine incorporation.
- Cytospin (Shandon, Cheshire, UK) prepared slides were stained with May-Grunwald Giemsa. The percentage of macrophage-like cells was determined by scoring at least 100 cells.
- Polystyrene latex particles (3.2 ⁇ diameter) (Sigma, St. Louis. MO) were added on day 3 of the assay as follows: Human serum was diluted 1 : 1 with saline and filtered through a 0.45 ⁇ filter (to remove insoluble particles). Then, 5x10 7 beads were added per ml diluted serum and incubated for 30 min at 37°C. This suspension was added at 0.1 ml/ml culture. Following 24 hr incubation, the cells were collected, washed twice with medium (in order to remove free latex particles) and the percentage of phagocytic cells was determined by scoring at least 200 cells, under an inverted microscope.
- PB peripheral blood
- BM bone marrow
- Mononuclear- enriched fractions were prepared by Ficoll Hypaque (Pharmacia. Milan, Italy) density gradient centrifugation, washed and frozen in liquid nitrogen. Prior to each experiment, cells were thawed and cultured at lxlO 6 cells/ml in alpha medium supplemented with 20% FCS and 10% conditioned medium from bladder carcinoma cell cultures (5637-CM).
- Peripheral bone mononuclear cells or BM cells obtained from normal volunteers were isolated by centrifugation on a gradient of Ficoll-Hypaque, and cloned in methylcellulose-containing alpha medium. For myeloid colonies, 30% FCS and CSF, in the form of 5637-CM or lOO U/ml GM-CSF, or IL-3 (Genetic institute, Cambridge, MA), 1% deionized BSA, lxl0" 5 M 2-mercaptoethanol and 1.5 mM glutamine were added.
- the culture included 30% FCS, 1% deionized BSA, 1.5 mM glutamine, 2-mercaptoethanol and 0.5-2 U/ml of erythropoietin (r-HuEPO, Cilag AG International, Switzerland).
- r-HuEPO erythropoietin
- One ml of the mixture containing either 2x10 5 BM or 5x10 5 PB cells was dispersed in 35 mm non- tissue culture dish (Falcon, Oxnared, CA). All semi-solid cultures were incubated at 37°C in a sealed incubator in humidified atmosphere of 6% O2, 7% CO2 and 87% N2. Colonies were scored with the aid of an inverted microscope.
- Example 4 Effects of SDF or its complex with CP on different cell cultures Effect on normal hemopoietic cells Expansion of normal hemopoietic progenitors - In order to test the effect of SDF on early and late normal hemopoietic progenitors a two-phase culture procedure was employed:
- Phase 1 Light density BM or PB cells were incubated for several days in liquid medium supplemented with SDF.
- Phase 2 (Clonal phase) - At the end of phase 1 , cells were harvested, washed and recultured in either semi solid medium or in liquid medium supplemented with either recombinant human late growth/differentiation factors like GM-CSF, Epo, or 5637-CM, which contains GM, G-CSF, IL-6, IL-1 and other cytokines. but not Epo.
- Phase 2 When BM or PB cells were incubated in Phase 1, for several days, with SDF as a sole factor, and then cloned (Phase 2) in SDF-free semi-solid medium, a significant expansion in the number of CFU-C was obtained (Fig. 9 A-B).
- the lineage specific differentiation of the colonies in Phase 2 depended on the late factor present, e.g., Epo for CFU-E and GM-CSF for CFU-GM.
- phase 1 expansion phase
- SDF by itself did not support colony development.
- SDF had a small or no stimulatory effect (data not shown).
- SDF is mostly active in the expansion phase of pre CFU-C, and by itself cannot support the proliferation and differentiation of CFU-C. It probably stimulates the proliferation of pre CFU-C, possibly by direct stimulation of expansion of CD34 + cells or by activation of accessory cells. Further proliferation and differentiation of CFU-C depends on the presence of late growth/ differentiation factors.
- Acute myeloid leukemia - SDF was found to be active, at very low concentrations, on different myeloid leukemic established cell-lines, e.g. HL-60 promyelocytic leukemic cells (Table 2), WEHI monoblast-like cells (Table 3), LK, a GM-CSF dependent myeloid leukemic cell line established in the inventors' laboratory (Table 4), as well as on freshly explanted cells from patients with various forms of myeloid leukemia (Tables 5-6).
- SDF-supplemented cultures the leukemic population underwent differentiation into fully mature macrophages.
- the cells changed their shape into typical macrophage morphology (Table 2), acquired macrophage functions such as mobility in semi-solid agar medium (assayed by the change of the colony morphology from "tight" to "diffused” (Table 3), the ability to phagocyte foreign particles (Tables 2 and 6), and to produce "non-specific” esterase (NSE) activity (Table 6).
- Table 2 typical macrophage morphology
- acquired macrophage functions such as mobility in semi-solid agar medium (assayed by the change of the colony morphology from "tight" to "diffused” (Table 3), the ability to phagocyte foreign particles (Tables 2 and 6), and to produce “non-specific” esterase (NSE) activity (Table 6).
- SDF is capable of inhibiting the growth of myeloid leukemia cells also in the absence of GM-CSF.
- AML-ALL cells Primary mixed AML-ALL cells were cultured at lxlO 6 cells/ml as indicated. Cells were analyzed on the sixth day of culture. In all four experiments, (A) to (D), non specific esterase and phagocytic cells were determined on the sixth day.
- Leukemic cells such as HL-60 cells, inhibit the development of normal BM cells.
- HL-60 cells were treated for 24 hrs with SDF, they lost their ability to inhibit normal hemopoietic development (Table 7).
- Table 7 The effect of HL-60 cells on development of normal BM colonies
- Viable HL-60 cells (lxlO 5 ) were incubated for 24 hours with or without SDF (1 :200 dilution) and then plated in agar as an underlay of normal BM cells. The number of BM colonies was determined on day 12.
- CML Chronic myeloid leukemia
- CML chronic myeloid leukemic patients
- SDF was cultured with CML colony forming cells (CFU-C) in a direct cloning procedure, utilizing a semi-solid culture and in an indirect cloning Procedure (two phase culture), as described herein before. These Cells retained their ability to differentiate but showed abnormal proliferation pattern. Therefore, is was concluded that SDF is capable of inhibiting the potential of these progenitors to proliferate and to develop colonies.
- CFU-C CML colony forming cells
- GM-CSF Different growth factors e.g. G-CSF.
- G-CSF Different growth factors e.g. G-CSF.
- GM-CSF are currently used in bone marrow transplantation. They have been shown to shorten neutrophil recovery time after transplantation (and chemotherapy) by stimulating myeloid progenitors.
- myeloid leukemic cells have receptors for these factors, the proliferation of residual malignant cells is also stimulated.
- SDF by itself or in combination with GM-CSF potentiates the proliferation of normal progenitors, but inhibits "spontaneous" and GM-CSF stimulated proliferation of myeloid leukemic cells, thus having a dual effect: eradication of leukemic cells concomitantly with stimulation of the normal ones.
- Example 5 Example 5
- the inventors have found that PQQ and related compounds induce differentiation in myeloid leukemic cells and stimulate the growth of early hemopoietic progenitor cells.
- the described effect is exemplified in Table 10.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU51331/98A AU731937B2 (en) | 1996-12-10 | 1997-12-01 | Serum-derived factor inducing cell differentiation and medical uses thereof |
IL13033597A IL130335A (en) | 1996-12-10 | 1997-12-01 | Serum-derived factor inducing cell differentiation and medical uses thereof |
JP52643698A JP2001505906A (en) | 1996-12-10 | 1997-12-01 | Serum-derived factor that induces cell differentiation and its pharmaceutical use |
CA002274469A CA2274469C (en) | 1996-12-10 | 1997-12-01 | Serum-derived factor inducing cell differentiation and medical uses thereof |
EP97946029A EP0973530A4 (en) | 1996-12-10 | 1997-12-01 | Serum-derived factor inducing cell differentiation and medical uses thereof |
US09/332,254 US6372262B1 (en) | 1996-12-10 | 1999-06-08 | Serum-derived factor inducing cell differentiation and medical uses thereof |
US09/986,503 US6783775B2 (en) | 1996-12-10 | 2001-11-09 | Serum-derived factor inducing cell differentiation and medical uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3264696P | 1996-12-10 | 1996-12-10 | |
US60/032,646 | 1996-12-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/332,254 Continuation US6372262B1 (en) | 1996-12-10 | 1999-06-08 | Serum-derived factor inducing cell differentiation and medical uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998025634A1 true WO1998025634A1 (en) | 1998-06-18 |
Family
ID=21866054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL1997/000395 WO1998025634A1 (en) | 1996-12-10 | 1997-12-01 | Serum-derived factor inducing cell differentiation and medical uses thereof |
Country Status (7)
Country | Link |
---|---|
US (2) | US6372262B1 (en) |
EP (1) | EP0973530A4 (en) |
JP (2) | JP2001505906A (en) |
AU (1) | AU731937B2 (en) |
CA (1) | CA2274469C (en) |
IL (1) | IL130335A (en) |
WO (1) | WO1998025634A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1117762A1 (en) * | 1998-09-29 | 2001-07-25 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US6887704B2 (en) | 1999-02-08 | 2005-05-03 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
CN108291202A (en) * | 2015-11-16 | 2018-07-17 | 山原研 | Cow's serum composition and use method of the cow's serum composition as additive culture cell |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL130335A (en) * | 1996-12-10 | 2004-09-27 | Hadasit Med Res Service | Serum-derived factor inducing cell differentiation and medical uses thereof |
US20100125265A1 (en) * | 2008-11-20 | 2010-05-20 | Medtronic Vascular, Inc. | Cell Delivery System to Induce Cell Growth and Angiogenesis |
CN102596234B (en) * | 2009-07-24 | 2016-11-16 | 罗得岛医院 | Dendritic cell vaccine for the tumor expressing asparaginyl--B-hydroxylase |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1304697A (en) * | 1970-02-11 | 1973-01-24 | ||
JPS60149529A (en) * | 1984-01-14 | 1985-08-07 | Mitsuyuki Shimizu | Production of differentiation induction factor for leukemia cells |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US466844A (en) * | 1892-01-12 | Salt-sprinkler for dough-cutting machines | ||
US4335116A (en) | 1980-10-07 | 1982-06-15 | University Patents, Inc. | Mineral-containing therapeutic compositions |
US5650147A (en) | 1981-09-08 | 1997-07-22 | The Rockefeller University | Methods of stimulating granulocyte-macrophage progenitor cells |
US4952607A (en) | 1982-05-27 | 1990-08-28 | International Copper Research Association, Inc. | Copper complex for treating cancer |
IL68218A (en) | 1983-03-23 | 1985-12-31 | Univ Ramot | Compositions for cartilage repair comprising embryonal chondrocytes |
US4666844A (en) | 1984-09-07 | 1987-05-19 | Sungene Technologies Corporation | Process for regenerating cereals |
US5120831A (en) | 1985-02-08 | 1992-06-09 | Procyte Corporation | Metal-peptide compositions |
US4935000A (en) | 1986-04-03 | 1990-06-19 | East Carolina University | Extracellular matrix induction method to produce pancreatic islet tissue |
GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
US5154931A (en) | 1986-10-22 | 1992-10-13 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Growth-stimulating material derived from porcine bone therefor and a manufacturing process |
US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
US4820531A (en) | 1987-10-22 | 1989-04-11 | Pioneer Hi-Bred International | Bacterial treatment to preserve hay quality by addition of microorganisms of the genus bacillus |
US4863747A (en) | 1987-10-22 | 1989-09-05 | Pioneer Hi-Bred International | Bacterial treatment to preserve hay quality by addition of microorganisms of the genus Bacillus |
US4932992A (en) | 1988-11-03 | 1990-06-12 | Tennessee Valley Authority | Dual purpose urease and nitrification inhibitors |
US5385933A (en) | 1989-02-27 | 1995-01-31 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5136025A (en) | 1990-04-04 | 1992-08-04 | California Biotechnology Inc. | Method to purify basic fibroblast growth factor |
US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
US5612211A (en) | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US5071872A (en) | 1990-08-14 | 1991-12-10 | The Ohio State University Research Foundation | Method for improving interleukin-2 activity using aci-reductone compounds |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
EP0562188B1 (en) * | 1992-03-27 | 1998-09-30 | Chung-Ho Chen | Composition for tissues to sustain viability and biological functions in surgery and storage |
US5807884A (en) | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
DE4240635C2 (en) | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Multiplication of hematopoietic progenitor cells ex vivo and compositions of hematopoietic growth factors |
EP0613946B1 (en) | 1993-02-12 | 2003-05-28 | Takeda Chemical Industries, Ltd. | hst-2 Mutein, DNA coding for the same and preparation thereof |
US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
JP3559585B2 (en) | 1993-06-03 | 2004-09-02 | 株式会社林原生物化学研究所 | Trehalose-releasing enzyme, its production method and use |
AU685506B2 (en) | 1993-08-25 | 1998-01-22 | Systemix, Inc. | Method for producing a highly enriched population of hematopoietic stem cells |
US5426098A (en) | 1993-09-02 | 1995-06-20 | Celtrix Pharmaceuticals, Inc. | Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta |
TW323222B (en) | 1993-12-27 | 1997-12-21 | Hayashibara Biochem Lab | |
NZ250858A (en) | 1993-12-27 | 1995-08-28 | Hayashibara Biochem Lab | Alkali-treated bagasse, its fermentation and use as animal feed |
US5565491A (en) | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
US5489304A (en) | 1994-04-19 | 1996-02-06 | Brigham & Women's Hospital | Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft |
US5666557A (en) * | 1994-06-16 | 1997-09-09 | Cassidy; Bruce Michael | Method and apparatus for automatically assigning device identifiers on a parallel data bus |
US5665557A (en) | 1994-11-14 | 1997-09-09 | Systemix, Inc. | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof |
US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US5637323A (en) | 1994-11-16 | 1997-06-10 | The United States Of America As Represented By The Department Of Health And Human Services | Method of mobilizing pluripotential hematopoietic stem cells with IL-7 |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5716616A (en) | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
US5733541A (en) | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
US5674750A (en) | 1995-05-19 | 1997-10-07 | T. Breeders | Continuous selective clonogenic expansion of relatively undifferentiated cells |
US5925567A (en) | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
US5728581A (en) | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
US5627070A (en) | 1995-07-26 | 1997-05-06 | Celltherapy, Inc. | Cell growing device for in vitro cell population expansion |
IL130335A (en) * | 1996-12-10 | 2004-09-27 | Hadasit Med Res Service | Serum-derived factor inducing cell differentiation and medical uses thereof |
EP1105463A1 (en) | 1998-08-24 | 2001-06-13 | t. Breeders, Inc. | Cell population containing non-fetal hemangioblasts and method for producing same |
-
1997
- 1997-12-01 IL IL13033597A patent/IL130335A/en not_active IP Right Cessation
- 1997-12-01 EP EP97946029A patent/EP0973530A4/en not_active Withdrawn
- 1997-12-01 WO PCT/IL1997/000395 patent/WO1998025634A1/en not_active Application Discontinuation
- 1997-12-01 JP JP52643698A patent/JP2001505906A/en active Pending
- 1997-12-01 CA CA002274469A patent/CA2274469C/en not_active Expired - Fee Related
- 1997-12-01 AU AU51331/98A patent/AU731937B2/en not_active Ceased
-
1999
- 1999-06-08 US US09/332,254 patent/US6372262B1/en not_active Expired - Fee Related
-
2001
- 2001-11-09 US US09/986,503 patent/US6783775B2/en not_active Expired - Fee Related
-
2004
- 2004-02-18 JP JP2004041646A patent/JP2004196816A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1304697A (en) * | 1970-02-11 | 1973-01-24 | ||
JPS60149529A (en) * | 1984-01-14 | 1985-08-07 | Mitsuyuki Shimizu | Production of differentiation induction factor for leukemia cells |
Non-Patent Citations (3)
Title |
---|
DARWISH H M, ET AL.: "MOBILIZATION OF COPPER (II) FROM PLASMA COMPONENTS AND MECHANISM OF HEPATIC COPPER TRANSPORT.", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 246, no. 9, 1 January 1984 (1984-01-01), US, pages G72 - G79, XP002965639, ISSN: 0002-9513 * |
LEHNINGER A.L., "The Molecular Basis of Cell Structure and Function", In: BIOCHEMISTRY, 2nd Edition, WORTH PUBLISHERS, INC., 1975, pages 73-75. * |
STEINKUEHLER C. ET AL: "Increase of Cu, Zn-Superoxide Dismutase Activity During Differentiation of Human K562 Cells Involves Activation by Copper of a Constantly Expressed Copper-Deficient Protein", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 266, no. 36, 25 December 1991 (1991-12-25), US, pages 24580 - 24587, XP002965195, ISSN: 0021-9258 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962698B1 (en) | 1998-02-17 | 2005-11-08 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
EP1117762A1 (en) * | 1998-09-29 | 2001-07-25 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
EP1117762A4 (en) * | 1998-09-29 | 2004-02-25 | Gamida Cell Ltd | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US6887704B2 (en) | 1999-02-08 | 2005-05-03 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
CN108291202A (en) * | 2015-11-16 | 2018-07-17 | 山原研 | Cow's serum composition and use method of the cow's serum composition as additive culture cell |
Also Published As
Publication number | Publication date |
---|---|
EP0973530A1 (en) | 2000-01-26 |
CA2274469A1 (en) | 1998-06-18 |
US6783775B2 (en) | 2004-08-31 |
US20020054916A1 (en) | 2002-05-09 |
US6372262B1 (en) | 2002-04-16 |
IL130335A (en) | 2004-09-27 |
AU5133198A (en) | 1998-07-03 |
AU731937B2 (en) | 2001-04-05 |
IL130335A0 (en) | 2000-06-01 |
CA2274469C (en) | 2009-09-01 |
JP2001505906A (en) | 2001-05-08 |
EP0973530A4 (en) | 2002-01-16 |
JP2004196816A (en) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5612211A (en) | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors | |
US4849329A (en) | Process for preparing lymphokine activated killer cells | |
Sachs | The control of growth and differentiation in normal and leukemic blood cells | |
US20100135969A1 (en) | Method of treating cancer using platelet releasate | |
US6372262B1 (en) | Serum-derived factor inducing cell differentiation and medical uses thereof | |
FI117468B (en) | Stem cell proliferation inhibitors | |
EP1069821B1 (en) | Method of controlling proliferation and differentiation of stem and progenitor cells | |
CA2249716A1 (en) | Inhibitor and stimulator of stem cell proliferation and uses thereof | |
Liao et al. | A novel polysaccharide of black soybean promotes myelopoiesis and reconstitutes bone marrow after 5-flurouracil-and irradiation-induced myelosuppression | |
AU6493794A (en) | Inhibitor of stem cell proliferation and uses thereof | |
CN115558641B (en) | High-purity effector immune cell population, culture method, reagent composition and application thereof | |
CN115651903B (en) | High-lethality immune cell population, and culture method, reagent composition and application thereof | |
US5258367A (en) | Uteroferrin and rose proteins for stimulating hematopoietic cells | |
KR102504039B1 (en) | Effective novel culture methods for the proliferation of natural killer cell and use thereof | |
Olofsson | Growth regulation of hematopoietic cells: an overview | |
Cesano et al. | Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or-resistant leukemic targets [see comments] | |
EP1150694B1 (en) | Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same | |
Huber et al. | Pteridines in the assessment of lymphocyte activation | |
McNiece et al. | The role of stem cell factor in the hematopoietic system | |
JP2747355B2 (en) | Human blood monocyte proliferation agent | |
WO1993016106A1 (en) | Novel megakaryocyte amplifier and production thereof | |
Agah et al. | Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations | |
Sachs | The control of growth and differentiation in normal and leukemic blood cells | |
Veldhuis et al. | Interleukin-3: its role in the physiopathology of allergy and clinical use in oncology | |
EP0135592A1 (en) | Dna synthesis-repressing substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2274469 Country of ref document: CA Kind code of ref document: A Ref document number: 2274469 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09332254 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 526436 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997946029 Country of ref document: EP Ref document number: 51331/98 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997946029 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 51331/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997946029 Country of ref document: EP |